what is selank?
from immune peptide to anxiolytic -- the tuftsin story
anxiety relief without the usual tradeoffs
selank is a synthetic heptapeptide derived from tuftsin, an endogenous immune-stimulating tetrapeptide. developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, selank was approved in Russia for the treatment of generalized anxiety disorder and as a nootropic. its defining feature is anxiolysis without sedation, cognitive impairment, or dependence -- a combination that no Western-approved anxiolytic achieves cleanly.
this course traces selank from its immunopeptide origins through its multi-target mechanism (GABA modulation, enkephalin stabilization, BDNF upregulation, IL-6 regulation), the clinical evidence that led to Russian approval, its remarkably clean safety profile, and the regulatory landscape that keeps it outside Western pharmacies.
the tuftsin connection
an immune peptide became an anxiolytic -- and that origin story matters.
tuftsin (Thr-Lys-Pro-Arg) is a naturally occurring tetrapeptide cleaved from the Fc region of immunoglobulin G. discovered in 1970, it stimulates phagocytosis and activates macrophages and neutrophils. Russian researchers at the Institute of Molecular Genetics added a Pro-Gly-Pro tail to the C-terminus of tuftsin, creating a seven-amino-acid peptide with dramatically different properties.
the Pro-Gly-Pro extension did two things: it increased metabolic stability by protecting the peptide from rapid enzymatic degradation, and it shifted the biological activity from primarily immunostimulatory to primarily neuromodulatory. the resulting molecule -- selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) -- retained some immune-modulating properties but gained potent anxiolytic and nootropic effects.
a multi-system neuromodulator
four mechanisms working together produce selank's anxiolytic and nootropic profile.
selank does not work through a single receptor like most anxiolytics. it modulates multiple neurotransmitter systems simultaneously: it enhances GABA-A receptor function without binding the benzodiazepine site, inhibits enkephalinase to stabilize endogenous opioid peptides, influences serotonin metabolism in the hypothalamus, and upregulates BDNF (brain-derived neurotrophic factor) expression in the hippocampus.
this multi-target approach may explain why selank produces anxiolysis without the tradeoffs associated with single-target drugs. benzodiazepines (GABA-A agonists) cause sedation and dependence. SSRIs (serotonin reuptake inhibitors) take weeks to work and cause sexual side effects. selank appears to achieve rapid anxiety reduction with neither of these problems.
approved in Russia
selank completed the Russian regulatory process -- this is not a gray-market research chemical.
unlike most peptides covered in this catalog, selank has actual regulatory approval. it was approved by the Russian Ministry of Health for the treatment of generalized anxiety disorder and neurasthenia (a Russian diagnostic category encompassing fatigue, irritability, and difficulty concentrating). it is available as a prescription nasal spray in Russian pharmacies.
the Russian approval was based on clinical trials conducted at multiple Russian research institutions. while these trials do not meet Western regulatory standards (smaller sample sizes, different methodological frameworks), they represent real clinical data from a functioning regulatory system. this places selank in a different evidence category than most research peptides, which have only animal data.
what you will learn
the course moves from immunopeptide origins through mechanisms, evidence, safety, and regulatory reality.
Knowledge Check
confirm the origins, mechanism basics, and regulatory fundamentals before moving deeper.
Practice
reinforce the distinctions that matter most for the rest of the course.